{
    "gs://literature-resources-bucket/Journal of Medicinal Chemistry/2025 Volume 68/01  (001-850)/0001-0017.pdf": {
        "title": "Recent Advances of Metal Complexes in the Treatment of Hepatocellular Carcinoma",
        "keywords": [
            "Hepatocellular Carcinoma, HCC",
            "Metal Complexes",
            "Chemotherapy",
            "Platinum complexes",
            "Anticancer agents",
            "Drug resistance",
            "Sorafenib",
            "Lenvatinib",
            "Regorafenib",
            "Cabozantinib",
            "Cisplatin",
            "Carboplatin",
            "Oxaliplatin",
            "Transarterial chemoembolization, TACE",
            "Patient-derived organoid, PDO",
            "Patient-derived tumor xenograft, PDX",
            "Abplatin(IV)",
            "Gold(I) complexes",
            "Barcelona clinic liver cancer, BCLC",
            "Surgical Resection",
            "Liver Transplantation",
            "Radiofrequency Ablation, RFA",
            "Systemic Therapy",
            "Multityrosine kinase inhibitor, TKI",
            "Vascular endothelial growth factor receptors, VEGFR",
            "Platelet-derived growth factor receptor, PDGFR",
            "Fibroblast growth factor receptor, FGFR",
            "Stem cell factor receptor, KIT",
            "Reactive oxygen species, ROS",
            "Endoplasmic reticulum stress, ERS",
            "Damage-related molecular patterns, DAMPs",
            "Immunogenic cell death, ICD",
            "Histone deacetylase, HDAC",
            "4-phenylbutyric acid, 4-PBA",
            "Benzothiazole aniline, BTA",
            "N-heterocyclic carbene, NHC",
            "Mitochondrial membrane potential, MMP",
            "Orotic acid, OA",
            "Dichloroacetate, DCA",
            "Tumor-immune microenvironment, TIME",
            "Auranofin, AF",
            "Thioredoxin reductase, TrxR",
            "Disulfiram",
            "Glycyrrhetinic acid, GA",
            "Ruthenium complexes",
            "Rhodium complexes",
            "Copper complexes",
            "Triphenylphosphine cation, TPP+",
            "Dynamic protein-associated protein 1, Drp1",
            "Pyrazolone-based copper complex",
            "2-(di(pyridin-2-yl)methylene)-N-(2-(trifluoromethyl)phenyl)-hydrazine-1-carbothioamide, ptpc",
            "2-(quinolin-8-ylmethylene)-N-(2-(trifluoromethyl)phenyl)hydrazine-1-carbothioamide, qtpc",
            "HAIC-cisplatin",
            "HAIC-oxaliplatin",
            "PI3K/AKT/mTOR signal pathways",
            "4-(2,3-dihydroxypropyl)-formamide oxygen alkyne, FOA",
            "2,2'-bipyridine, bpy",
            "1,10-phenanthroline, phen",
            "4,4'-dimethyl-2,2'-bipyridine, dmb",
            "Human hepatocytes, BEL-7402",
            "Ru-\u03b2-Ala-FQHPSFI complex",
            "HCBP1 peptide",
            "NAD-SIRT1-AMPK axis",
            "ATP-AMPK-mTOR-SREBP1 pathway",
            "Nephrotoxicity",
            "Neurotoxicity",
            "Ototoxicity",
            "Nausea",
            "Vomiting",
            "Diarrhea",
            "Hypertension",
            "Hand-foot syndrome",
            "HMGB1",
            "DNA damage",
            "Apoptosis",
            "Mito-dysfunction",
            "Caspase-dependent",
            "Autophagy",
            "Cell cycle arrest",
            "G2/M phase",
            "S phase",
            "G1 phase",
            "Antitumor immune response",
            "Hypoxia active",
            "Oxidative DNA damage",
            "Immuno-chemotherapeutics",
            "C-terminal acidic tail",
            "DNA structural motifs",
            "Platinum(IV) drug",
            "Low-toxicity",
            "Liver-targeting",
            "Mitochondria-targeting",
            "4,5-diarylimidazole Pt(II)-N-heterocyclic carbene",
            "Type II immunogenic cell death inducer",
            "Monounsaturated fatty acids",
            "Hepatic venous pressure gradient",
            "Indocyanine green clearance model",
            "Percutaneous ethanol injection, PEI",
            "Microwave ablation, MWA",
            "Cryoablation",
            "Percutaneous laser ablation, PLA",
            "Irreversible electroporation, IRE",
            "Stereotactic body radiotherapy, SBRT",
            "High-intensity focused ultrasound, HIFU",
            "5-year overall survival, OS",
            "Progression-free survival, PFS",
            "Hepatocyte growth factor receptor, HGF",
            "Angiopoietin receptors TIE-2",
            "c-Kit",
            "FLT-3",
            "Platinum derivatives",
            "S-1 (new oral 5-FU analogue)",
            "Curcumin coloaded nanoliposomes",
            "Anti-inflammatory agents",
            "Anti-HIV",
            "Gold thiomalate sodium",
            "Gold glucose",
            "Albumin",
            "Proteasome system",
            "NF-kB",
            "Sulfhydryl groups",
            "Selenol groups",
            "Aldehyde dehydrogenase",
            "Morin",
            "TRAIL receptor DR4/DR5",
            "IAP family members",
            "Halogen and halogen-like gold(I)-NHC complexes",
            "Antiproliferative activity",
            "Cyclometalated iridium (III) complex",
            "CGAS-STING pathways"
        ]
    },
    "gs://literature-resources-bucket/Journal of Medicinal Chemistry/2025 Volume 68/01  (001-850)/0018-0048.pdf": {
        "title": "The Potential of PARP Inhibitors as Antitumor Drugs and the Perspective of Molecular Design",
        "keywords": [
            "PARP (Poly-ADP ribose polymerase)",
            "PARPis (PARP inhibitors)",
            "Antitumor drugs",
            "Molecular design",
            "DNA damage repair",
            "Synthetic lethality",
            "BRCA deficient tumors",
            "BRCA1/BRCA2 deficiencies",
            "Breast cancer",
            "Ovarian cancer",
            "Prostate cancer",
            "Pancreatic cancer",
            "Clinical efficacy",
            "Drug resistance",
            "Selective PARP-1 inhibitors",
            "PROTACs (Proteolysis Targeting Chimeras)",
            "Cancer treatment strategy",
            "Genomic instability",
            "TME (Tumor microenvironment)",
            "Immune evasion",
            "Metabolic reprogramming",
            "Metastasis",
            "Genetic mutations",
            "Oncogenic mutations",
            "Angiogenesis",
            "Immune response",
            "Immune cell recognition",
            "Immune cell activation",
            "Immune suppressive cells",
            "Nicotinamide adenine dinucleotide (NAD+)",
            "ADP-ribose",
            "PAR (Poly(ADP-ribose))",
            "DNA repair pathways",
            "HR (Homologous recombination)",
            "NHEJ (Nonhomologous end joining)",
            "Double-strand break repair",
            "Zinc finger DBD (DNA-binding domain)",
            "Automodification domain (AMD)",
            "Catalytic domain",
            "BRCT (BRCA1 C-terminal) domain",
            "WGR (Tryptophan-glycine-arginine-rich domain)",
            "DNA repair mechanism",
            "HRR (Homologous Recombination Repair)",
            "HRD (Homologous Recombination Defect)",
            "MRN (MRE11-RAD50-NBS1) complex",
            "ssDNA (Single-stranded DNA)",
            "ATM kinase",
            "BRCA-BRAD complex",
            "DSBs (DNA double-strand breaks)",
            "RAD51",
            "DNA ligase",
            "Competitive inhibition",
            "Substrate binding",
            "Enzymatic activity",
            "PAR chain formation",
            "Apoptosis",
            "Caspase-3",
            "Bcl-2",
            "IAP-1",
            "Mcl-1",
            "TRCs (Transcription-replication conflicts)",
            "TIMELESS",
            "TIPIN",
            "Alt-EJ (Alternative end joining)",
            "SSB (Single strand break)",
            "XRCC1 (X-ray repair cross-complementing protein 1)",
            "Ku70/80",
            "Clinical development",
            "Combination therapy",
            "Predictive biomarkers",
            "Genomic profiling",
            "Molecular diagnostics",
            "DNA repair gene alterations",
            "PFS (Progression-free survival)",
            "OS (Overall survival)",
            "mCRPC (Metastatic castration-resistant prostate cancer)",
            "CK2-mediated p53R2 phosphorylation",
            "Immune checkpoint inhibitors",
            "PD-1 inhibitors",
            "Hematotoxicity",
            "Pharmacological efficacy",
            "Commercially available PARPis",
            "Olaparib",
            "Niraparib",
            "Rucaparib",
            "Talazoparib",
            "Fuzuloparib",
            "Pamiparib",
            "Senaparib (IMPACT)",
            "Veliparib (ABT888)",
            "Saruparib (AZD5305)",
            "BGB-290 (Pamiparib)",
            "Structural modification",
            "Selectivity enhancement",
            "Targeting improvement",
            "3-AB (3-aminobenzamide)",
            "Isoindolinone",
            "Benzimidazole",
            "Benzofuran",
            "Benzothiazole",
            "Naphthyridone",
            "Radiosensitization",
            "Chemosensitization",
            "cGAS-STING pathway",
            "Ubiquitin-proteasome system (UPS)"
        ]
    },
    "gs://literature-resources-bucket/Journal of Medicinal Chemistry/2025 Volume 68/01  (001-850)/0049-0080.pdf": {
        "title": "A Collection of Novel Antitumor Agents That Regulate Lipid Metabolism in the Tumor Microenvironment",
        "keywords": [
            "Lipid metabolism",
            "Tumor microenvironment",
            "Antitumor agents",
            "Lipid metabolism reprogramming",
            "Lipid uptake",
            "De novo lipogenesis",
            "Fatty acid oxidation (FAO)",
            "Cholesterol synthesis",
            "Regulatory factors",
            "Metabolic changes in tumors",
            "Warburg effect",
            "Lipid storage",
            "Lipid droplets (LDs)",
            "Low-density lipoprotein (LDL)",
            "High-density lipoprotein (HDL)",
            "Fatty acid (FA) synthesis pathway",
            "Acetyl-CoA carboxylase (ACC)",
            "FA synthase (FASN)",
            "Stearoyl-CoA desaturase (SCD)",
            "Triacyl glycerol (TAG)",
            "Cholesteryl ester (CE)",
            "Medicinal chemistry",
            "Drug discovery",
            "Small molecule agents",
            "Tumor cell proliferation",
            "Tumor cell survival",
            "Tumor cell invasion",
            "Tumor cell metastasis",
            "Metabolic adaptation",
            "Glucose metabolism",
            "Signal transduction",
            "GPCRs (Guanine-nucleotide-binding protein coupled receptors)",
            "PI3K-AKT pathway",
            "PTEN/PI3K/AKT axis",
            "mTOR (Mammalian targets of Rapamycin)",
            "SREBP (Sterol regulatory element binding protein)",
            "Hypoxia",
            "Energy deficiency",
            "pH instability",
            "Antifibrosis drugs",
            "CD36 (Cluster of Differentiation 36)",
            "FA-binding protein (FABP)",
            "FA transport protein (FATP)",
            "ox-LDL (Oxidized low-density lipoprotein)",
            "JAK2/STAT3 pathway",
            "GHRP-6 (Growth hormone releasing peptide 6)",
            "LXR (Liver X receptor)",
            "ABC transporter (ATP-binding cassette transporter)",
            "CPT (Carnitine Palmitoyl Transferase)",
            "CPT1A",
            "CPT1C",
            "Mitochondrial integrity",
            "Ferroptosis",
            "L-carnitine",
            "Malonyl coenzyme A",
            "ST-1326",
            "Etomoxir",
            "ACLY (ATP-Citrate Lyase)",
            "Citric acid",
            "HCA (Hydroxycitric acid)",
            "SB-204990",
            "NDI-091143",
            "BMS-303141",
            "ER stress (Endoplasmic Reticulum stress)",
            "p-eIF2a/ATF4/CHOP axis",
            "ACACA (Acetyl coenzyme A carboxylase a)",
            "LNCaP cells",
            "ChREBPs (Carbohydrate response element binding proteins)",
            "Biperidine derivatives",
            "CP-640186",
            "4-Piperidinyl piperazine derivatives",
            "Spiropiperidine derivatives",
            "Aryl ether derivatives",
            "Methylthienopyrimidinedione derivatives",
            "Firsocostat (ND-630)",
            "ND-646",
            "KS domain (\u03b2-ketoacyl synthase domain)",
            "KR domain (Keto reductase domain)",
            "ACP domain (Acyl carrier protein domain)",
            "TE domain (Thioesterase domain)",
            "Cerulenin",
            "Thiolactomycin",
            "Orlistat (Xenical)",
            "Aliphatic amide derivatives",
            "Biaryl derivatives",
            "Benzoyl tertiary amine derivatives",
            "TVB-2640",
            "DGAT (Diglyceride Acyltransferase)",
            "DGAT1",
            "DGAT2",
            "Cholesterol acyltransferase (ACAT)",
            "Benzimidazole derivatives",
            "Biarylurea derivatives",
            "FXR (Farnesol X Receptor)",
            "Bile acids",
            "CYP7A1 (Cholesterol 7-hydroxylase)",
            "FXR agonists",
            "Steroid derivatives",
            "Cholic acid (CA)",
            "CDCA (Chenodeoxycholic acid)",
            "6-ECDCA (Obeticholic acid, OCA, INT-747)",
            "GW4064",
            "3-Benzamidobenzoic acid derivatives",
            "Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives",
            "Fexaramine",
            "ATX (Autotaxin)",
            "ATX-LPA axis",
            "Phosphoric acid derivatives",
            "LPA (Lysophosphatidic acid)",
            "Benzyl 4-methylpiperazine-1-carboxylate derivatives",
            "PF-8380",
            "Imidazo[1,2-a]pyridine derivatives",
            "Indole derivatives",
            "TUDCA (Tauroursodeoxycholic acid)",
            "UDCA (Ursodeoxycholic acid)"
        ]
    },
    "gs://literature-resources-bucket/Journal of Medicinal Chemistry/2025 Volume 68/01  (001-850)/0081-0094.pdf": {
        "title": "Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein",
        "keywords": [
            "RET kinase",
            "rearranged-during-transfection (RET)",
            "oncogenic RET",
            "RET-altered cancers",
            "selpercatinib (LOXO-292)",
            "pralsetinib (BLU-667)",
            "kinase inhibitors",
            "PROTAC, proteolysis targeting chimera",
            "degraders",
            "YW-N-7",
            "KIF5B-RET",
            "xenograft tumors",
            "in vitro",
            "in vivo",
            "dual action",
            "proteomic analysis",
            "CCDC6-RET",
            "LOXO-292, selpercatinib",
            "BLU-667, pralsetinib",
            "human cancer cells",
            "RET fusion oncogene",
            "RXDX-105",
            "FDA-approved doses",
            "dose reduction",
            "treatment-related adverse events",
            "thyroid cancer patients",
            "NSCLC, non-small cell lung cancer",
            "primary resistance",
            "on-target resistance",
            "off-target resistance",
            "medullary thyroid cancer (MTC)",
            "papillary thyroid cancer (PTC)",
            "chromosomal rearrangements",
            "driver oncogenes",
            "colorectal cancer",
            "pancreatic cancer",
            "RET-positive cancers",
            "RET fusion genes",
            "TKIs, selective protein tyrosine kinase inhibitors",
            "ATP-competitive RET inhibitors",
            "human TPC1 thyroid cancer cells",
            "LC-2/ad nonsmall cell lung cancer cells",
            "autor-egulatory mechanism",
            "E3 ligase",
            "CRBN, cereblon",
            "PG, phenyl glutarimide",
            "lenalidomide",
            "Hook effect",
            "hydrophobic linker",
            "hydrophilic linker",
            "rigid linker",
            "ubiquitin E3 ligase binding ligand",
            "IMiDs, immunomodulatory imide drugs",
            "VHL, von Hippel-Lindau tumor suppressor",
            "CUL2-RBX1-ElongB/C-VHL (CRL2VHL) ubiquitin ligase",
            "CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ligase",
            "ternary complex",
            "ubiquitination",
            "proteasomal degradation",
            "target-binding ligand",
            "linker composition",
            "linker length",
            "coupling position",
            "chemical stability",
            "SAR, structure-activity relationship",
            "EGFR, epidermal growth factor receptor",
            "pERK1/2",
            "ERK1/2",
            "BaF3 cells",
            "JAK2, Janus kinase 2",
            "BaF3/TEL-VEGFR cells",
            "VEGR2, vascular endothelial growth factor receptor 2",
            "BaF3/KIF5B-RET cells",
            "IMR-90 human diploid fibroblasts",
            "ME-Y-N-7",
            "bortezomib",
            "proteasome inhibitor",
            "TMT, tandem mass tag",
            "mass spectrometric proteomic analysis",
            "differentially expressed (DE) proteins",
            "CDK2, cyclin-dependent kinase 2",
            "AURKA/B, Aurora kinase A/B",
            "MKI67",
            "CDKN1B",
            "PK, pharmacokinetics",
            "cell-derived xenograft (CDX) tumors",
            "intraperitoneal injection",
            "tumor size",
            "tumor weight",
            "immunoblotting analysis",
            "Tyr-905-phosphorylated KIF5B-RET",
            "half-life time",
            "B/KR cell-derived xenografted mouse tumor model",
            "research tool",
            "RET-targeted therapy",
            "oral bioavailability",
            "biphasic dose-dependent response",
            "combination therapy",
            "high-affinity ligands",
            "flexible linker",
            "rigid linker"
        ]
    },
    "gs://literature-resources-bucket/Journal of Medicinal Chemistry/2025 Volume 68/01  (001-850)/0095-0107.pdf": {
        "title": "TKK130 is a 3-Hydroxy-Propanamidine (HPA) with Potent Antimalarial In Vivo Activity and a High Barrier to Resistance",
        "keywords": [
            "Malaria",
            "Plasmodium falciparum",
            "Antimalarial drug",
            "3-Hydroxypropanamidine (HPA)",
            "TKK130",
            "TKK129",
            "Drug resistance",
            "In vivo activity",
            "\u03b2-hematin",
            "Hemozoin",
            "Dihydroartemisinin",
            "Chloroquine (CQ)",
            "Lumefantrine (LUM)",
            "Halofantrine (Hf)",
            "Parasite selectivity",
            "Cytotoxicity",
            "HepG2 cells",
            "HEK293 cells",
            "HeLa cells",
            "Selectivity index (SI)",
            "Parasite reduction ratio (PRR)",
            "Resistance development",
            "Single-step selection assay",
            "Mutator strain",
            "Dd2 Pold",
            "DSM265",
            "Clinical isolates",
            "Gabon",
            "Multidrug-resistant parasites",
            "Heme detoxification pathway",
            "NP-40 detergent assay",
            "Pharmacokinetics",
            "Plasma stability",
            "Blood-to-plasma ratio",
            "Microsomal stability",
            "Human liver microsomes (HLMs)",
            "Plasma protein binding (PPB)",
            "Equilibrium dialysis",
            "Hepatic clearance",
            "Hepatic extraction ratio",
            "hERG potassium channel inhibition",
            "Cardiotoxicity",
            "Plasmodium berghei mouse model",
            "Peters test",
            "Cure rate",
            "Mean survival days (MSD)",
            "Snapshot pharmacokinetics",
            "Linear pharmacokinetics",
            "Maximum concentration (Cmax)",
            "Time to maximum concentration (tmax)",
            "Area under the curve (AUCo-t)",
            "Benzamidine moiety",
            "Phenanthrene moiety",
            "Phenanthridines",
            "Phenanthrolines",
            "Bioisosteric replacement",
            "4-Methoxy group",
            "Fluorine substituent",
            "Metabolic stability",
            "Anti-plasmodial profile",
            "Trimethylaluminum",
            "4-Fluoroaniline",
            "3-Hydroxypropanenitrile",
            "Chemical stability",
            "Aqueous solution",
            "Phosphate buffer",
            "P. knowlesi",
            "Zoonotic malaria",
            "IC50",
            "Atovaquone",
            "Pyrimethamine",
            "HRP2 ELISA",
            "Ex vivo susceptibility",
            "Lambar\u00e9n\u00e9",
            "In vitro studies",
            "Laboratory-adapted strains",
            "Cross-resistance",
            "Antimalarial targets",
            "Docking calculations",
            "Adsorption energy",
            "Size-independent ligand efficiency (SILE)",
            "Non-hydrogen atoms",
            "In vitro pharmacokinetic evaluation",
            "Elimination half-life",
            "Red blood cell (RBC) fraction",
            "Intrinsic clearance (Clint)",
            "Microsomal binding",
            "Unbound fraction",
            "Dilution method",
            "Itraconazole",
            "Low extraction compound",
            "Arylamino alcohol antimalarials",
            "Combination partners",
            "Synergistically acting antimalarials",
            "Imaging studies",
            "Drug distribution",
            "Metabolism",
            "Organ-specific metabolism",
            "Mode of action studies",
            "Biocrystallization process",
            "(001) crystal face",
            "Mosquirix",
            "R21/Matrix-M",
            "Artemisinin-based combination therapies",
            "Partial resistance",
            "Drug development",
            "Pfatp4",
            "PfeEF2",
            "Pfcarl",
            "PfcytB",
            "PfACOAS"
        ]
    },
    "gs://literature-resources-bucket/Journal of Medicinal Chemistry/2025 Volume 68/01  (001-850)/0108-0134.pdf": {
        "title": "Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma",
        "keywords": [
            "3,4-Dihydroisoquinolin-1(2H)-one derivatives",
            "Protein Arginine Methyltransferase 5, PRMT5",
            "PRMT5 inhibitors",
            "Non-Hodgkin's Lymphoma, NHL",
            "Scaffold hopping strategy",
            "SAR, Structure-Activity Relationship",
            "Z-138 xenograft models",
            "Antiproliferative activity",
            "hERG toxicity",
            "Molecular docking",
            "Molecular dynamic (MD) simulation",
            "Surface plasmon resonance, SPR",
            "Drug metabolism and pharmacokinetics, DMPK",
            "Hematological malignancies",
            "Hodgkin's lymphoma, HL",
            "B-cell NHL",
            "Protein methylation modifications",
            "w-NG, NG-asymmetric dimethyl, aDMA",
            "w-NG-monomethyl arginine, MMA",
            "S-adenosylmethionine, SAM",
            "Substrate-competitive inhibitors",
            "SAM-competitive inhibitors",
            "Combined SAM/substrate-competitive inhibitors",
            "Methylosome protein 50, MEP50",
            "Hetero-octamer",
            "Transcriptional regulation",
            "Chromatin remodeling",
            "Cell cycle regulation",
            "Acute myeloid leukemia, AML",
            "Myelodysplastic syndrome, MDS",
            "Hematological toxicity",
            "Nonalcoholic fatty liver disease",
            "Homeostatic hematopoiesis",
            "Hematopoiesis genes",
            "Pyrimidine carboxamide",
            "3,4-dihydroisoquinolin-1(2H)-one scaffold",
            "H-bond",
            "Hydrophobic interaction",
            "Cation-\u03c0 interaction",
            "\u03c0-\u03c0 stacking interaction",
            "Tritiated methyl",
            "CCK-8 assay",
            "Symmetric dimethylarginine",
            "Western blot analysis",
            "Cell apoptosis assay",
            "Annexin-V-FITC/PI staining",
            "Flow cytometry experiment",
            "Cell cycle assay",
            "G0/G1 phase arrest",
            "In vivo antitumor evaluation",
            "Xenograft model",
            "Tumor growth inhibitory values",
            "Maximum tolerated dose, MTD",
            "In vitro DMPK profiles",
            "Metabolic stability",
            "Liver microsomes",
            "Plasma protein binding rate",
            "Cytochrome P450, CYP450 isoforms",
            "Aminoalkylation reaction",
            "Internal amination reaction",
            "Nucleophilic substitution",
            "Coupling reaction",
            "Alkylation",
            "Lactamization",
            "Nitration",
            "Reduction",
            "Boc-protected piperidin-4-one",
            "Deprotection",
            "Acylation",
            "Cyanation",
            "Cyclization",
            "Bromination",
            "Ru catalyst, Ruthenium catalyst",
            "MM-GBSA, Molecular mechanics-generalized Born surface area",
            "Binding energy",
            "Van der Waals energy",
            "Electrostatic energy",
            "Polar solvation energy",
            "Nonpolar solvation energy",
            "Protein-ligand interaction",
            "Selectivity profiling",
            "Arginine methyltransferases",
            "PRMT1, Protein arginine methyltransferase 1",
            "PRMT3, Protein arginine methyltransferase 3",
            "PRMT4, Protein arginine methyltransferase 4",
            "PRMT6, Protein arginine methyltransferase 6",
            "PRMT7, Protein arginine methyltransferase 7",
            "PRMT8, Protein arginine methyltransferase 8",
            "IC50, Half maximal inhibitory concentration",
            "Myeloid cells",
            "Erythrocytes",
            "Megakaryocytes",
            "Histological staining",
            "Antitumor mechanism",
            "SmD3me2s",
            "Oral toxicity",
            "Potent antitumor agent",
            "Clinical trials",
            "Medicinal Chemistry",
            "Drug design",
            "Chemical synthesis",
            "Biological evaluation",
            "Structure optimization",
            "Lead optimization",
            "Candidate",
            "Preclinical",
            "Compound D3",
            "GSK3326595"
        ]
    },
    "gs://literature-resources-bucket/Journal of Medicinal Chemistry/2025 Volume 68/01  (001-850)/0135-0155.pdf": {
        "title": "Guardians at the Gate: Optimization of Small Molecule Entry Inhibitors of Ebola and Marburg Viruses",
        "keywords": [
            "Ebola virus, EBOV",
            "Marburg virus, MARV",
            "Filoviral infections",
            "Hemorrhagic fevers",
            "FDA-approved therapeutics",
            "Small molecule therapeutics",
            "Unmet medical need",
            "Structural optimization",
            "Lead compound",
            "N-(4-(4-methylpiperidin-1-yl)-3-(trifluoromethyl)phenyl)-4-(morpholinomethyl)benzamide",
            "Hit-to-lead effort",
            "Structure-activity relationship, SAR",
            "Pseudotyped EBOV",
            "Pseudotyped MARV",
            "Antiviral activities",
            "Ebolaviruses",
            "Off-target activity",
            "Druglike properties",
            "In vivo efficacy studies",
            "Drug discovery campaign",
            "RNA viruses",
            "WHO's top 10 global health threats",
            "Category A Bioterrorism agents",
            "CDC",
            "COVID-19 pandemic",
            "Antiviral drugs",
            "Vaccines",
            "Filoviridae family",
            "Single-stranded, enveloped, and negative sense-RNA viruses",
            "Viral hemorrhagic fevers",
            "Fatality rates",
            "Sub-Saharan Africa",
            "EBOV/MARV antiviral agents",
            "Ervebo",
            "Zabdeno/Mvabea",
            "Zaire EBOV",
            "Sudan species of ebolaviruses",
            "Broad-spectrum antifiloviral agents",
            "Direct-acting antivirals, DAAs",
            "Viral proteins",
            "Viral replication cycle",
            "Host-targeted antivirals, HTA",
            "Host factors",
            "Small molecule inhibitors",
            "FDA-approved drugs",
            "EBOV inhibitors",
            "Galidesivir",
            "Favipiravir",
            "Remdesivir",
            "Viral polymerases",
            "Glycoprotein (GP) inhibitors",
            "Toremifene",
            "Clomiphene",
            "Amiodarone",
            "FGI-104",
            "Coumarin-based antihistaminic",
            "Benzoquinoline compounds",
            "Clinical trials",
            "Supportive care",
            "Pandemic potential",
            "High-throughput screen",
            "4-(aminomethyl)-benzamide-based hit compound",
            "CBS1118",
            "Micromolar inhibition",
            "EBOV-GP",
            "Pseudoviral assay",
            "Entry inhibitors",
            "Mechanism of action, MOA",
            "Optimized analogs",
            "pEBOV",
            "pMARV",
            "BSL-4 facility",
            "A549 cells",
            "MARV-GP",
            "EBOV-GP pseudoviruses",
            "Lead optimization strategy",
            "Morpholine ring A",
            "Phenyl rings B",
            "Phenyl rings C",
            "Amide linker",
            "Hydrophobic ring D",
            "4-methylpiperidine",
            "Aliphatic amines",
            "Isopropyl",
            "tert-butyl",
            "3,5-dimethylpiperidine",
            "Gem-dimethyl analog",
            "Pyrrolidine",
            "Azetidine",
            "Morpholinyl",
            "4-methylpiperazinyl",
            "Spirocyclic groups",
            "Spiro[3.3]-heptanes",
            "Azabicyclo nonane substituent",
            "Aqueous solubility",
            "Metabolic stability",
            "Three-dimensionality",
            "Adamantyl group",
            "Deconstructed analog",
            "Chloro substituent",
            "Fluoro substituent",
            "Trifluoromethyl group",
            "Thiazole ring",
            "3,5-disubstituted thiazole",
            "1,4-disubstituted phenyl ring",
            "Carbamides",
            "Hydrogen bond donor",
            "Urea moiety",
            "Retroamide",
            "Pyridine analogs",
            "Bridged morpholine moiety",
            "Submicromolar MARV inhibition",
            "Sudan variant, SUDV",
            "Tai Forest, pTFV",
            "Reston, pRESTV",
            "Bundibugyo, pBDBV",
            "Infection data",
            "Wild-type, WT",
            "HeLa cells",
            "Submicromolar potencies",
            "Selectivity index, SI",
            "EBOV-GP cocrystallized with toremifene",
            "PDB ID: 5JQ7",
            "Glycoproteins, GP1",
            "Glycoproteins, GP2",
            "Molecular interactions",
            "Toremifene binding site",
            "Hydrogen bond interactions",
            "Thr519",
            "T519 V-EBOV mutant",
            "Azaspiro[3.5]nonane ring",
            "Hydrophobic pocket",
            "Leucine residues",
            "Isoleucine residues",
            "Cation-\u03c0 interaction",
            "Guanidine nitrogen atoms of Arg64",
            "Carbonyl oxygen",
            "Asp522",
            "Surface Plasmon Resonance, SPR",
            "MARV- and EBOV-GP share only ~28% amino acid identity",
            "Crystal structure of MARV-GP",
            "Cationic amphiphilic drugs",
            "Phospholipidosis",
            "Drug-induced phospholipidosis, DIPL",
            "Lysosomal accumulation",
            "ADMET properties",
            "Pharmacokinetics analysis",
            "hERG channel",
            "Cardiotoxicity"
        ]
    },
    "gs://literature-resources-bucket/Journal of Medicinal Chemistry/2025 Volume 68/01  (001-850)/0156-0173.pdf": {
        "title": "Novel PD-L1/VISTA Dual Inhibitor as Potential Immunotherapy Agents",
        "keywords": [
            "PD-L1, Programmed cell death 1 ligand 1",
            "VISTA, V-domain immunoglobulin suppressor of T cell activation",
            "Dual-target inhibitor",
            "Immunotherapy",
            "Immune checkpoint proteins",
            "Antitumor activity",
            "T cell activation",
            "Drug design",
            "P17",
            "Signaling pathways",
            "Protein level",
            "Cellular level",
            "Druggability",
            "Safety assessments",
            "Antitumor efficacy",
            "In vivo experiments",
            "Immune cell infiltration",
            "Therapeutic potential",
            "Hypoxia",
            "IFN-\u03b3, Interferon-gamma",
            "HIF-1\u03b1, Hypoxia-inducible factor 1-alpha",
            "Methionine metabolism",
            "YTHDF1, YTH N6-Methyladenosine RNA Binding Protein F1",
            "m6A, N6-methyladenosine",
            "Monocytes",
            "JAK-STAT-IRF1 signaling pathway",
            "Naive T cells",
            "Peripheral immune tolerance",
            "Immune escape",
            "Upregulation",
            "Pharmacokinetic, PK",
            "Toxicological assessments",
            "Clinical trials",
            "Molecular glue",
            "PD-1, Programmed cell death protein 1",
            "Dimerization",
            "Hydrophobic interactions",
            "Hydrogen bonds",
            "Q66A residue",
            "D122B residue",
            "Cellular experiments",
            "H292 cell line",
            "PBMCs, Peripheral blood mononuclear cells",
            "Immunofluorescence analysis",
            "Cell impedance assays",
            "VISTA pathway",
            "Intermolecular interactions",
            "Phe68, Phenylalanine 68",
            "Tyr69, Tyrosine 69",
            "Lys70, Lysine 70",
            "VISTA mutants",
            "Cytotoxicity",
            "H1975 cell line",
            "A549 cell line",
            "Apoptosis",
            "CD3 stimulation",
            "CD28 stimulation",
            "NK cells, Natural killer cells",
            "SKOV3 cell line",
            "Coculture model",
            "Protein-protein interactions, PPI",
            "CA-170",
            "BMS202",
            "A4",
            "TR-FRET, Time-resolved fluorescence resonance energy transfer",
            "MST, Microscale thermophoresis",
            "Biphenyl structure",
            "Ethanolamine structure",
            "Pyrimidine ring",
            "Chemical synthesis",
            "Sodium methoxide",
            "3-Bromo-2-methylaniline",
            "3-Bromo-2-fluoroaniline",
            "Methanesulfonic acid",
            "Sodium borohydride",
            "Phenylboronic acid",
            "Pd(dppf)Cl2, [1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)",
            "Thionyl chloride",
            "Structure optimization",
            "Activity evaluation",
            "Structure-activity relationships",
            "Stereoisomers",
            "Electron-donating substituents",
            "Electron-withdrawing substituents",
            "Binding affinity",
            "Cocrystal structure",
            "Molecular docking",
            "In vivo pharmacodynamic evaluation",
            "LLC-C57BL/6 mouse model",
            "LLC-Balb/c-nude mice",
            "CD8+ T cell infiltration",
            "IFNy+CD8+ T cells",
            "GzmB+CD8+ T cells, Granzyme B+CD8+ T cells",
            "Tregs, Regulatory T cells",
            "M1-type macrophages",
            "M2-type macrophages",
            "Immunohistochemical staining",
            "TUNEL staining, TdT-mediated dUTP Nick-End Labeling",
            "Combination drug strategies",
            "Coexpression mechanisms",
            "Monoclonal antibodies",
            "Scaffold fusion strategy",
            "Methyl 2-chloro-6-methoxypyrimidine-4-carboxylate",
            "HPLC, High-performance liquid chromatography",
            "HRMS, High-resolution mass spectrometry"
        ]
    }
}